Matthew R. Cooperberg

Matthew R. Cooperberg

Auto-generated profile, based on publicly available information

Matthew R. Cooperberg

Department of Urology, University of California, San Francisco, San Francisco, CA, USA

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2010 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
MCMatthew R. Cooperberg
Matthew R. Cooperberg
JBJeanette M. Broering
Jeanette M. Broering
PCPeter R. Carroll
Peter R. Carroll
Purpose: In the absence of high-level evidence or clinical guidelines supporting any given active treatment approach over another for localized prostate cancer, clinician and patient preferences may lead to substantial variation in treatment use. Methods: Data were analyzed from 36 clinical sites that contributed data to the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) registry. Distribution of primary treatment use was measured over time. Prostate cancer risk was assessed using the D'Amico risk groups and the Cancer of the Prostate Risk Assessment (CAPRA) score. Descriptive analyses were performed, and a hierarchical model was constructed that controlled for year of diagnosis, cancer risk variables, and other patient factors to estimate the proportion of variation in primary treatment selection explicable by practice site. Results: Among 11,892 men analyzed, 6.8% elected surveillance, 49.9% prostatectomy, 11.6% external-beam radiation, 13.3% brachytherapy, 4.0% cryoablation, and 14.4% androgen deprivation monotherapy. Prostate cancer risk drives treatment selection, but the data suggest both overtreatment of low-risk disease and undertreatment of high-risk disease. The former trend appears to be improving over time, while the latter is worsening. Treatment varies with age, comorbidity, and socioeconomic status. However, treatment patterns vary markedly across clinical sites, and this variation is not explained by case-mix variability or known patient factors. Practice site explains a proportion of this variation ranging from 13% for androgen deprivation monotherapy to 74% for cryoablation. Conclusion: Substantial variation exists in management of localized prostate cancer that is not explained by measurable factors. A critical need exists for high-quality comparative effectiveness research in localized prostate cancer to help guide treatment decision making.

1 June 2005 in Journal of Urology
Verified
Journal Article
Closed access
MCMatthew R. Cooperberg
Matthew R. Cooperberg
DPDavid J. Pasta
David J. Pasta
EEEric P. Elkin
Eric P. Elkin
MLMark S. Litwin
Mark S. Litwin
DLDavid M. Latini
David M. Latini
PCPeter R. Carroll
Peter R. Carroll
Purpose: Multivariate prognostic instruments aim to predict risk of recurrence among patients with localized prostate cancer. We devised a novel risk assessment tool which would be a strong...

7 July 2015 in JAMA
Verified
Journal Article
Open access
PDF file
MCMatthew R. Cooperberg
Matthew R. Cooperberg
PCPeter R. Carroll
Peter R. Carroll
A growing literature supports the safety and efficacy of active surveillance for patients with low-risk prostate cancer. However, the experience behind this literature is based almost entirely in academic centers, and prior reports have consistently found surveillance generally underused in most other settings.1,2 Conversely, high-risk tumors have been undertreated with androgen deprivation treatment alone.2,3 Recent trends in community-based practice patterns have not been well documented.

20 June 2008 in Cancer
Verified
Journal Article
Open access
PDF file
CKChristopher J. Kane
Christopher J. Kane
KMKatherine Mallin
Katherine Mallin
JRJamie Ritchey
Jamie Ritchey
MCMatthew R. Cooperberg
Matthew R. Cooperberg
PCPeter R. Carroll
Peter R. Carroll
BACKGROUND.: Evidence exists to suggest a pattern of increasing early diagnosis of renal cell carcinoma (RCC). The aim of the study was to analyze patterns of disease presentation and outcome of RCC by AJCC stage using data from the National Cancer Data Base (NCDB) over a 12‐year period.METHODS.: The NCDB was queried for adults diagnosed between 1993 and 2004 presenting with ICD‐O‐2 of 3 renal cell tumors arising in the kidney. Cases were classified by demographics, 2002 AJCC stage (6th edition), and histology. The Cochran‐Armitage Test for Trend was used to determine statistical significance of trends over time. Cox regression multivariate analysis was used to evaluate the impact of stage and histology on relative survival. SPSS 14.0 was used for analyses.RESULTS.: Between 1993 and 2004 a total of 205,963 patients from the NCDB fit our case definition of RCC. Comparisons between 1993 and 2004 data show an increase in stage I disease and decrease in stage II, III, and IV disease (P ≤ .001). The size of stage I tumors also decreased from a mean of 4.1 cm in 1993 to 3.6 cm in 2003. In multivariate analysis, stage, but not histology, predicted relative survival. A 3.3% increase in survival was found for patients diagnosed in 1998 compared with patients diagnosed in 1993.CONCLUSIONS.: A greater proportion of newly diagnosed patients with RCC currently present with stage I disease compared with earlier years. Stage predicts relative survival for patients with kidney cancer. More recently diagnosed patients have improved relative survival. Cancer 2008. © 2008 American Cancer Society.

1 June 2004 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
MCMatthew R. Cooperberg
Matthew R. Cooperberg
DLDeborah P. Lubeck
Deborah P. Lubeck
MMMaxwell V. Meng
Maxwell V. Meng
SMShilpa S. Mehta
Shilpa S. Mehta
PCPeter R. Carroll
Peter R. Carroll
Purpose: Early intervention for prostate cancer is associated with excellent long-term survival, but many affected men, especially those with low-risk disease characteristics, might not experience adverse impact to survival or quality of life were treatment deferred. We sought to characterize temporal trends in clinical presentation and primary disease management among patients with low-risk prostate cancer. Methods: Data were abstracted from the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE), a disease registry of 8,685 men with various stages of prostate cancer. Included were 2,078 men who were diagnosed between 1989 and 2001 and had a serum prostate specific antigen ≤ 10 ng/mL, Gleason sum ≤ 6, and clinical T stage ≤ 2a. Trends in risk distribution, tumor characteristics, and primary treatment were evaluated. Results: The proportion of patients with low-risk tumor characteristics rose from 29.8% in 1989 to 1992, to 45.3% in 1999 to 2001 (P < .0001). There have been sharp increases in the use of brachytherapy and androgen deprivation monotherapy, from 3.1% and 3.1%, to 12.0% and 21.7%, respectively. Utilization rates for prostatectomy, external-beam radiotherapy, and observation have fallen accordingly, from 63.8%, 16.1%, and 13.8%, to 51.6%, 6.8%, and 7.9% (P < .0001 for all except prostatectomy [P = .0019]). Age and socioeconomic status were significantly associated with treatment selection, but overall, the treatment trends were echoed on subgroup analysis of patients 75 years or older. Conclusion: Low-risk features characterize a growing proportion of prostate cancer patients, and there have been significant shifts in the management of low-risk disease. Overtreatment may be a growing problem, especially among older patients.

3 June 2011 in Cancer
Verified
Journal Article
Open access
PDF file
MCMatthew R. Cooperberg
Matthew R. Cooperberg
JHJoan F. Hilton
Joan F. Hilton
PCPeter R. Carroll
Peter R. Carroll
BACKGROUND: The authors previously developed and validated the Cancer of the Prostate Risk Assessment (CAPRA) score to predict prostate cancer recurrence based on pretreatment clinical data. They aimed to develop a similar postsurgical score with improved accuracy via incorporation of pathologic data.METHODS: A total of 3837 prostatectomy patients in the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE™) national disease registry were analyzed. Cox regression was used to determine the predictive power of preoperative prostate‐specific antigen (PSA), pathologic Gleason score (pGS), surgical margins (SM), extracapsular extension (ECE), seminal vesicle invasion (SVI), and lymph node invasion (LNI). Points were assigned based on the relative weights of these variables in predicting recurrence. The new postsurgical score (CAPRA‐S) was tested and compared with a commonly cited nomogram with proportional hazards analysis, concordance (c) index, calibration plots, and decision‐curve analysis.RESULTS: Recurrence appeared in 16.8% of the men; actuarial progression‐free probability at 5 years was 78.0%. The CAPRA‐S was determined by adding up to 3 points for PSA, up to 3 points for pGS, 1 point each for ECE and LNI, and 2 points each for SM and SVI. The hazard ratio for each point increase in CAPRA‐S score was 1.54 (95% confidence interval, 1.49‐1.59), indicating a 2.4‐fold increase in risk for each 2‐point increase in score. The CAPRA‐S c‐index was 0.77, substantially higher than 0.66 for the pretreatment CAPRA score and comparable to 0.76 for the nomogram. The CAPRA‐S score performed better in both calibration and decision curve analyses.CONCLUSIONS: The CAPRA‐S offers good discriminatory accuracy, calibration, and ease of calculation for clinical and research settings. Cancer 2011;. © 2011 American Cancer Society.